Cell line · CVCL_0213
Papers40
1 to 20 of 40
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Site and mechanism of BK channel inhibition and cerebral artery constriction by pregnenolone. | Pharmacol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Mass Spectrometry-Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio-Biodistribution. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Improving Anti-CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Zinc-Mediated Lysosomal Destabilization Links Mitochondrial Damage to Neuronal Death in a Cellular MPP+ Model of Parkinson's Disease. | J Neurochem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NGF promotes, in an autocrine-paracrine manner, metabolic and anti-inflammatory pathways in human and mouse adipocytes. | J Clin Endocrinol Metab | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NIR Ratiometric Fluorescent Antibody-Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular basis of domain-specific angiotensin I-converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat, quinaprilat and perindoprilat. | FEBS J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase. | Antib Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. | J Immunother Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dnajc5b contributes to male fertility by maintaining the mitochondrial functions and autophagic homeostasis during spermiogenesis. | Cell Mol Life Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
Differential Cytotoxic Effects of Cell-Free Supernatants of Emerging Pathogens Escherichia albertii and Escherichia fergusonii on Four Cell Lines Reveal Vero Cells as a Putative Candidate for Cytotoxicity Analysis. | Microorganisms | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of a novel variant in KCNJ16, encoding Kir5.1 channel. | Physiol Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Alternative method to visualize receptor dynamics in cell membranes. | PLoS One | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation. | Bioconjug Chem | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer. | Pharmaceutics | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Calcium-sensing receptor regulates Kv7 channels via Gi/o protein signalling and modulates excitability of human induced pluripotent stem cell-derived nociceptive-like neurons. | Br J Pharmacol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors. | EMBO Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy. | MAbs | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization. | Theranostics | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0213/papers